Trial Profile
Phase I Study of the Metabolism and Excretion of [14C]-Rigosertib After Single-dose Administration as 24-hour Continuous Intravenous Infusion to Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 28 Jun 2017
Price :
$35
*
At a glance
- Drugs Rigosertib (Primary)
- Indications Cancer; Haemoblastosis
- Focus Pharmacokinetics
- Sponsors Onconova Therapeutics
- 14 Sep 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrial.gov record.
- 31 Jul 2015 Planned End Date changed from 1 Jul 2015 to 1 Nov 2015 as reported by ClinicalTrial.gov record.
- 26 May 2014 Planned End Date changed from 1 Jul 2014 to 1 Jul 2015 as reported by ClinicalTrial.gov record.